(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer

AIM: Targeting the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is a potential means of overcoming chemoresistance in ovarian cancer. We investigated the capability of (18)F-fluororodeoxyglucose ((18)F-FDG) small-animal positron emission tomography (SA-PET) to predic...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lheureux, Stéphanie, Lecerf, Charlotte, Briand, Mélanie, Louis, Marie-Hélène, Dutoit, Soizic, Jebahi, Abdelghani, Giffard, Florence, Fournier, Cécile Blanc, Batalla, Alain, Poulain, Laurent, Aide, Nicolas
Format: Artigo
Langue:Inglês
Publié: Neoplasia Press Inc. 2013
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3799200/
https://ncbi.nlm.nih.gov/pubmed/24151539
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires